CLARITIN HIVES RELIEF REDITAB Drug Patent Profile
✉ Email this page to a colleague
When do Claritin Hives Relief Reditab patents expire, and when can generic versions of Claritin Hives Relief Reditab launch?
Claritin Hives Relief Reditab is a drug marketed by Bayer Healthcare Llc and is included in one NDA.
The generic ingredient in CLARITIN HIVES RELIEF REDITAB is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty suppliers are listed for this compound. Additional details are available on the loratadine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Hives Relief Reditab
A generic version of CLARITIN HIVES RELIEF REDITAB was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.
Summary for CLARITIN HIVES RELIEF REDITAB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 148 |
| Patent Applications: | 2,967 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CLARITIN HIVES RELIEF REDITAB at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CLARITIN HIVES RELIEF REDITAB
US Patents and Regulatory Information for CLARITIN HIVES RELIEF REDITAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | CLARITIN HIVES RELIEF REDITAB | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CLARITIN HIVES RELIEF REDITAB
See the table below for patents covering CLARITIN HIVES RELIEF REDITAB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S5735586 | NOVEL ANTIHISTAMIC | ⤷ Try a Trial |
| Hungary | 186774 | PROCESS FOR PREPARING NEW ANTIHISTAMINES | ⤷ Try a Trial |
| Spain | 8300779 | ⤷ Try a Trial | |
| Hungary | T41731 | ⤷ Try a Trial | |
| Japan | S61289087 | PRODUCTION OF PYPERIDILIDENE HYDRODIBENZO(A, D) CYCLOHEPTENES AND AZA DERIVATIVES THEREOF, COMPOUND OBTAINEDAND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLARITIN HIVES RELIEF REDITAB
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0152897 | 2001C/013 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
| 0152897 | SPC/GB01/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
| 1110543 | SPC/GB08/005 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| 0152897 | C00152897/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| 1110543 | 08C0004 | France | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
